(Reuters) – Genome sequencing company Human Longevity Inc plans to go public through a merger with Freedom Acquisition I Corp that values the combined company at about $1 billion, the two companies said on Monday. The announcement followed the signing of a non-binding letter of intent, although the companies said that there is no assurance of a definitive agreement or completion of a deal. Freedom Acquisition I Corp is a special purpose acquisition company led by former Credit Suisse chief executive Tidjane Thiam, and was listed early last year. A blank-check firm, or a special purpose acquisi…